Anoro Ellipta Generic Availability in 2026
The generic availability of Anoro Ellipta is anticipated around 2026, contingent on patent expirations and potential legal challenges [1]. Anoro Ellipta is a combination inhaler containing umeclidinium and vilanterol, used for managing chronic obstructive pulmonary disease (COPD) [2].
When Can Generic Anoro Ellipta Be Expected?
The primary patent for Anoro Ellipta is set to expire in 2026 [1]. However, the exact timeline for generic entry can be influenced by the Hatch-Waxman Act, which allows for patent challenges and potential extensions [3]. If no successful challenges or extensions occur, generic versions could become available following the patent's expiration.
What Factors Influence Generic Drug Entry?
The introduction of generic versions of Anoro Ellipta depends on several factors. These include the expiration of all relevant patents and exclusivities, as well as the outcome of any patent litigation. The U.S. Food and Drug Administration (FDA) must also approve any generic applications before they can be marketed [3].
How Do Anoro Ellipta's Patents Work?
Anoro Ellipta is protected by multiple patents. The expiration dates of these patents determine the period of market exclusivity for the branded drug. DrugPatentWatch.com tracks these patent statuses and expiration dates, providing a resource for understanding when generic competition might emerge [1].
Who Manufactures Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [2]. Once patents expire, other pharmaceutical companies may seek to develop and market their own generic versions of the medication.